Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

Lignende værker

• A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
  af: Russo, Alessandro, et al.
  Udgivet: (2015)
• Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
  af: Russo, Alessandro, et al.
  Udgivet: (2018)
• Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site
  af: Franchina, Tindara, et al.
  Udgivet: (2016)
• Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
  af: Russo, Alessandro, et al.
  Udgivet: (2019)
• Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
  af: Ricciardi, Giuseppina Rosaria Rita, et al.
  Udgivet: (2015)